相关实验视频
Updated: Sep 19, 2025

10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
22.1K
盘状纳米粒子利用血栓诱导的剪切梯度来增强中风中的特定位点血栓溶解
Chunping Liu1, Jiaoyang Wang1, Zhenhua Wang1
1Institute of Biomedical Engineering, College of Medicine, Southwest Jiaotong University, Chengdu 610031, China; Key Laboratory of Advanced Technologies of Materials Ministry of Education, School of Materials Science and Engineering, Southwest Jiaotong University, Chengdu 610031, China.
Acta biomaterialia
|June 15, 2025
概括
携带组织等离子体激活剂 (tPA) 的 discoidal 纳米粒子显示出改善了治疗缺血性中风的向性. 它们独特的形状增强了血液凝块的传递,改善了血栓溶解和恢复血液流动.
科学领域:
- 生物医学工程 生物医学工程
- 纳米医学是一种纳米医学.
- 血管生物学 血管生物学
背景情况:
- 血栓塞栓性中风涉及由于动脉血栓形成的脑缺血.
- 组织等离子素激活剂 (tPA) 是一种标准的血栓缓解剂,但具有狭窄的治疗窗口等局限性.
- 在有效的血栓向方面,tPA的纳米粒子传递面临着挑战,受粒子形态和血流剪切应激的影响.
研究的目的:
- 调查纳米粒子形态学对血栓向和血栓溶解疗效的影响.
- 开发一种改进的基于纳米粒子的tPA在缺血性中风治疗中的传递系统.
主要方法:
- 制造的聚 (乳酸-co-糖酸) (PLGA) 纳米颗粒在球形,棒形和圆形形状.
- 对tPA与制造的纳米颗粒的结合.
- 在高剪压条件下评估纳米粒子边缘化,血栓粘附和血栓解压活性.
主要成果:
- 盘状tPA结合纳米粒子 (D-tPA) 在高切削应力下表现出增强的边缘化和偏好的粘附力.
- 与球形和棒形纳米粒子相比,D-tPA显示出更好的血栓溶解.
- 通过D-tPA治疗观察到大脑输液的成功恢复.
结论:
- 在中风治疗中,粒子形状是有效的血管药物递送的关键因素.
- 盘状PLGA纳米颗粒代表了针对性血栓解压疗法在缺血性中风的有希望的策略.
- 这种方法为血管疾病的更有效和更有针对性的纳米医学治疗提供了潜力.
相关概念视频
Venous Thrombosis III: Interprofessional Care
28
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
28
Anticoagulant Drugs: Low-Molecular-Weight Heparins
932
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
932
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Clot Retraction and Fibrinolysis
6.9K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.9K

